Tasly News

Tasly Biopharmaceuticals Co.,Ltd. got a license agreement with Takara Bio

Source:Tasly Biopharmaceuticals Co.,Ltd.

Tasly Biopharmaceuticals Co.,Ltd.(headquarters in Shanghai,PRC)has entered into a license agreement with Takara Bio(Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan) for exclusive development, manufacturing and commercialization of Oncolytic Virus C-REV in china. 

Canerpaturev(C-REV) is an attenuated strain of the herpes simplex virus type 1 (HSV-1) that demonstrates anti-tumor activity when locally injected into a tumor. This type of virus is called “oncolytic virus.” Oncolytic viruses do not replicate inside of normal cells while selectively replicate in tumor cells and break them down without excessively damaging normal cells.